Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Thanarajasingam G, Kim HT, Cutler C, Ho VT, Koreth J, Alyea EP, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(12):1713–18.

    Article  Google Scholar 

  2. Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(3):454–9.

    Article  Google Scholar 

  3. Soiffer R, Chen Y. Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. Blood Adv. 2017;1(25):2473–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Mehta SV, Shukla SN, Vora HH. Overexpression of Bcl2 protein predicts chemo resistance in acute myeloid leukemia: its correlation with FLT3. PubMed PMID: 23906301. Neoplasma . 2013;60(6):666–75.

    Article  CAS  Google Scholar 

  5. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–17.

    Article  CAS  Google Scholar 

  6. Pollyea DA, Dinardo CD, Thirman MJ, Letai A, Wei AH, Jonas BA. Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy. J Clin Oncol. 2016;34(15_suppl):7009.

    Article  Google Scholar 

  7. Duléry R, Ménard AL, Chantepie S, El-Cheikh J, François S, Delage J, et al. Sequential conditioning with thiotepa in T cell-replete hematopoietic stem cell transplantation for the treatment of refractory hematologic malignancies: comparison with matched related, haplo-mismatched, and unrelated donors. Biol Blood Marrow Transplant. 2018;24(5):1013–21.

    Article  Google Scholar 

  8. Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA et al. Management of venetoclax - posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;359–367.

    Article  CAS  Google Scholar 

  9. Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia. 2012;26(11):2353–59.

    Article  CAS  Google Scholar 

  10. Craddock C, Labopin M, Robin M, Finke J, Chevallier P, Yakoub-Agha I, et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2016;101(7):879–83.

    Article  CAS  Google Scholar 

  11. Takami A, Yano S, Yokoyama H, Kuwatsuka Y, Yamaguchi T, Kanda Y, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014;20(11):1785–90.

    Article  Google Scholar 

  12. Kharfan-Dabaja MA, Labopin M, Polge E, Nishihori T, Bazarbachi A, Finke J, et al. Adoptive cellular therapy with donor lymphocyte infusion versus a second allogeneic hematopoietic cell transplant for post-allograft relapsed acute myeloid leukemia: an intent-to-treat analysis on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Blood. 2017;130(suppl 1):273.

    Google Scholar 

  13. DiNardo CD, Pollyea DA, Jonas BA, Konopleva M, Pullarkat V, Wei A, et al. Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment naive, elderly patients with acute myeloid leukemia. Blood . 2017;130(Suppl 1):2628.

    Google Scholar 

  14. DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–07.

    Article  CAS  Google Scholar 

  15. Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM. et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica. 2018. https://doi.org/10.3324/haematol.2018.188094.

    Article  Google Scholar 

  16. Liu B, Narurkar R, Hanmantgad M, Zafar W, Song Y, Liu D, et al. Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report. Front Med. 2018. https://doi.org/10.1007/s11684-018-0635-y

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Ali Bazarbachi or Jean El-Cheikh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moukalled, N.M., El Darsa, H., Haibe, Y. et al. Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation. Bone Marrow Transplant 54, 620–624 (2019). https://doi.org/10.1038/s41409-018-0347-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0347-6

This article is cited by

Search

Quick links